C4 Therapeutics Inc (NASDAQ:CCCC) has a beta value of -73.75% and has seen 1.1 shares traded in the last trading session. The company, currently valued at $100.83M, closed the last trade at $1.44 per share which meant it lost -$14.36 on the day or 1.42% during that session. The CCCC stock price is -431.94% off its 52-week high price of $7.66 and 24.31% above the 52-week low of $1.09. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.15 million shares traded. The 3-month trading volume is 0.96 shares.
The consensus among analysts is that C4 Therapeutics Inc (CCCC) is Hold stock at the moment, with a recommendation rating of 45.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 3 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.39.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Sporting 1.42% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CCCC stock price touched $1.44 or saw a rise of 17.24%. Year-to-date, C4 Therapeutics Inc shares have moved -65.70%, while the 5-day performance has seen it change -12.35%. Over the past 30 days, the shares of C4 Therapeutics Inc (NASDAQ:CCCC) have changed -4.05%. Short interest in the company has seen 6.17 million shares shorted with days to cover at 6.32.
Wall Street analysts have a consensus price target for the stock at $13.5, which means that the shares’ value could jump 89.33% from current levels. The projected low price target is $10.0 while the price target rests at a high of $20.0. In that case, then, we find that the current price level is -1288.89% off the targeted high while a plunge would see the stock gain -594.44% from current levels.
C4 Therapeutics Inc (CCCC) estimates and forecasts
The company’s shares have lost -67.05% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -36.08%.
6 analysts offering their estimates for the company have set an average revenue estimate of 5.37M for the current quarter. 6 have an estimated revenue figure of 5.7M for the next ending quarter. Year-ago sales stood 12.01M and 15.36M respectively for this quarter and the next, and analysts expect sales will shrink by -55.30% for the current quarter and -36.08% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 5.90% -8.92% over the past 5 years. Earnings growth for 2025 is a modest -12.41% while over the next 5 years, the company’s earnings are expected to increase by 6.31%.
CCCC Dividends
C4 Therapeutics Inc is expected to release its next earnings report on 2025-May-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
Insiders own 9.79% of the company shares, while shares held by institutions stand at 91.87% with a share float percentage of 101.83%. Investors are also buoyed by the number of investors in a company, with C4 Therapeutics Inc having a total of 162.0 institutions that hold shares in the company. The top two institutional holders are LYNX1 CAPITAL MANAGEMENT LP with over 6.88 million shares worth more than $31.79 million. As of 2024-06-30, LYNX1 CAPITAL MANAGEMENT LP held 9.9993% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 4.88 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.54 million and represent 7.0891% of shares outstanding.
